• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, January 20, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Influenza-neutralizing antibodies generated in human subjects given experimental vaccine

Bioengineer by Bioengineer
July 7, 2016
in Immunology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

RC-Crowe-lab

Influenza A viruses are responsible for seasonal disease outbreaks in humans. Influenza A also circulates among bird and some mammal populations and periodically crosses between species.

The influenza A H3N2 variant (H3N2v) virus, which circulates in swine, has recently been reported in humans, especially children, and is distinct from other seasonal H3N2 strains found in humans. So far, H3N2v has only been reported in individuals that have had direct contact with pigs and causes a fairly severe disease.

Current vaccines that promote immunity to seasonal human H3N2 strains do not protect against H3N2v. In this issue of JCI Insight, James Crowe of Vanderbilt University and colleagues describe the isolation and characterization of monoclonal antibodies with H3N2v-neutralizing capacity from human subjects given an H3N2v candidate vaccine. While these antibodies effectively neutralized H3N2v, they were not effective against currently circulating human H3N2 strains. However, these antibodies were able to neutralize human H3N2 strains that circulated between 1995 and 2005, indicating that these strains are highly related to H3N2v. Moreover, these results help explain why young children, who have not been exposed to earlier H3N2 strains, are so susceptible to H3N2v infection.

###

TITLE:

Recognition of influenza H3N2 variant virus by human neutralizing antibodies

AUTHOR CONTACT:

James E. Crowe, Jr.
Vanderbilt University Medical Center
Email: [email protected]

View this article at: http://insight.jci.org/articles/view/86673?key=cd5ec95d2c86e63ad430

JCI Insight is the newest publication from the American Society of Clinical Investigation, a nonprofit honor organization of physician-scientists. JCI Insight is dedicated to publishing a range of translational biomedical research with an emphasis on rigorous experimental methods and data reporting. All articles published in JCI Insight are freely available at the time of publication. For more information about JCI Insight and all of the latest articles go to http://www.insight.jci.org.

Media Contact

Corinne Williams
[email protected]
@jclinicalinvest

http://www.jci.org

The post Influenza-neutralizing antibodies generated in human subjects given experimental vaccine appeared first on Scienmag.

Share79Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Heart attack patients in England ‘fearful’ of seeking medical help amid COVID crisis

January 19, 2021
IMAGE

5G doesn’t cause COVID-19, but the rumor it does spread like a virus

January 19, 2021

Research establishes antibiotic potential for cannabis molecule

January 19, 2021

Where COVID-19 hit hardest, sudden deaths outside the hospital increased

January 18, 2021
Next Post
blank

Early antiretroviral therapy reduces gut inflammation in HIV+ individuals

blank

A step towards palliative care policy in Africa

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • New drug form may help treat osteoporosis, calcium-related disorders

    40 shares
    Share 16 Tweet 10
  • People living with HIV face premature heart disease and barriers to care

    60 shares
    Share 24 Tweet 15
  • Blood pressure drug may be key to increasing lifespan, new study shows

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsChemistry/Physics/Materials SciencesMedicine/HealthCell BiologyClimate ChangePublic HealthcancerBiologyTechnology/Engineering/Computer ScienceEcology/EnvironmentInfectious/Emerging DiseasesMaterials

Recent Posts

  • Breakthrough in understanding ‘tummy bug’ bacteria
  • Stealing the spotlight in the field and kitchen
  • Genome editing to treat human retinal degeneration
  • Do simulations represent the real world at the atomic scale?
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In